Novartis highlights depth of immunology pipeline with novel

Pivotal results for efficacy and safety of Cosentyx ® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress.

Related Keywords

United States , America , American , Isabella Zinck , Michael Meo , Rachel Fink Thoma , Nicole Zinsli Somm , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Angelika Jahreis , Alina Levchuk , European Academy Of Dermatology , Clinical Development Excellence , Twitter , Novartis Us External Communications , International Symposium On Sjo , Novartis , Exchange Commission , Novartis Pharmaceuticals Communications , Global Head Development Unit Immunology , European Academy , International Symposium , Dose Ranging Trial , Terrible Toll , Understanding Sjo , Autoimmune Diseases , Congress , Disease , Information Technology , Nhs , Pharmaceuticals , Social Media , Canakinumab , Hidradenitis Suppurativa , Medication , Omalizumab ,